Skip to main content
Delfa

← Trials/Trial dossier/NCT00627848

ADFRMI

CompletedPhase NA

Rivastigmine in Mild Alzheimer's Disease, FMRI Study

Effect of Rivastigmine on FMRI in Mild Alzheimer's Disease

Asset

Rivastigmine

Listed sites

1

Recruiting sites

-

Enrollment

20

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Alzheimer's disease

Primary endpoint

•FMRI response in face recognition task

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDKUH5772749
NCT IDNCT00627848

Timeline

Milestones

Study start2007-03 (month precision)
Study first posted2008-03-03estimated
Primary completion2008-12actual (month precision)
Study completion2008-12actual (month precision)
Last update posted2011-10-28estimated

Assets

Drug assets

Rivastigmine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years
Maximum age85 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Probable Alzheimer's disease according to the NINCDS-ADRDA criteria
•mild disease, CDR 1
•the clinician is planning to start anticholinesterase treatment

Exclusion criteria

•cognitive impairment for other reason than Alzheimer's disease
•severe depression
•other unstable physical disease
•medal in body prevention MRI examination, claustrophobia
•cardiac pacemaker
•other significant neurologic or psychiatric disease
•contraindication for anticholinesterase treatment

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition
1
Memory
1

Global cognition

1 endpoint
Secondary/protocol endpoint

treatment response measured by ADAS-cog

Time frame:at 6 month and 1 year

ADAS-Cog

descriptive

Memory

1 endpoint
Primary/protocol endpoint

FMRI response in face recognition task

Time frame:at baseline and at 1 mo

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.